Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Haukeland University Hospital
The primary outcome is monitor for toxicity effect for the combination therapy.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to participate
You may not be if
Patient participated in an investigational study within 30 days prior to study entry (or, if longer, within five half-lives of the last dose of any investigational drug).
Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.
Patient has a history of cardiovascular ischemia, acute myocardial infarction or unstable angina within 3 months prior to study entry.
Patient has a history of any psychiatric disorder or cognitive impairment that would interfere with participation in the study.
Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.
Patient requires dialysis or has severely impaired renal function, defined as a serum creatinine \> 180 mmol/L at the Screening Visit.
Patient has severe impairment of liver function, defined as a serum albumin level ≤ 25 g/L and/or a Protrombin Time INR \> 2.3 (or APTT \> 6 seconds above the upper limit of normal) at the Screening Visit.
Patient is pregnant or is breast-feeding.
Patient is allergic to or intolerant of gemcitabine
Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent
Any reason why, in the opinion of the investigator, the patient should not participate.
Clareo Health | Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer
